Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.

Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E.

Allergy. 2012 May;67(5):630-7. doi: 10.1111/j.1398-9995.2012.02801.x. Epub 2012 Mar 3.

PMID:
22385366
[PubMed - indexed for MEDLINE]
2.

Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.

Jung K.

Allergy. 2011 Jul;66 Suppl 95:41-3. doi: 10.1111/j.1398-9995.2011.02632.x.

PMID:
21668852
[PubMed - indexed for MEDLINE]
3.

Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.

Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E.

Clin Ther. 2012 Oct;34(10):2072-81. doi: 10.1016/j.clinthera.2012.09.006.

PMID:
23063373
[PubMed - indexed for MEDLINE]
4.
5.

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.

Rask C, Lund L, Lund G, Heydenreich B, Wurtzen P, Bellinghausen I, Saloga J, Lund K.

Clin Exp Allergy. 2012 Sep;42(9):1356-68. doi: 10.1111/j.1365-2222.2012.04026.x.

PMID:
22925322
[PubMed - indexed for MEDLINE]
6.

Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.

Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.

Clin Ther. 2011 Jul;33(7):828-40. doi: 10.1016/j.clinthera.2011.06.006. Epub 2011 Jul 7.

PMID:
21741092
[PubMed - indexed for MEDLINE]
7.

Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.

Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R.

Allergy. 2011 Sep;66(9):1174-82. doi: 10.1111/j.1398-9995.2011.02592.x. Epub 2011 Apr 11.

PMID:
21480924
[PubMed - indexed for MEDLINE]
8.

Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.

Klimek L, Schendzielorz P, Pinol R, Pfaar O.

Clin Exp Allergy. 2012 Jun;42(6):936-45. doi: 10.1111/j.1365-2222.2012.03971.x.

PMID:
22909165
[PubMed - indexed for MEDLINE]
9.

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.

Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.

J Allergy Clin Immunol. 2006 Apr;117(4):802-9.

PMID:
16630937
[PubMed - indexed for MEDLINE]
10.

Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.

Gadermaier E, Flicker S, Aberer W, Egger C, Reider N, Focke M, Vrtala S, Kundi M, Valenta R.

Int Arch Allergy Immunol. 2010;151(1):17-27. doi: 10.1159/000232567. Epub 2009 Aug 6.

PMID:
19672093
[PubMed - indexed for MEDLINE]
11.

A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.

Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Bräutigam M, Klimek L.

Allergy. 2012 Feb;67(2):272-9. doi: 10.1111/j.1398-9995.2011.02736.x. Epub 2011 Nov 23.

PMID:
22107266
[PubMed - indexed for MEDLINE]
12.

The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.

Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Saçkesen C, Kalayci O.

Pediatr Allergy Immunol. 2006 Sep;17(6):396-407.

PMID:
16925684
[PubMed - indexed for MEDLINE]
13.

Sustained effects of grass pollen AIT.

Durham SR; GT-08 investigators.

Allergy. 2011 Jul;66 Suppl 95:50-2. doi: 10.1111/j.1398-9995.2011.02639.x.

PMID:
21668855
[PubMed - indexed for MEDLINE]
14.

Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.

Pfaar O, van Twuijver E, Hecker H, Boot JD, van Ree R, Klimek L.

Int Arch Allergy Immunol. 2013;160(4):420-4. doi: 10.1159/000343026. Epub 2012 Nov 23.

PMID:
23183541
[PubMed - indexed for MEDLINE]
15.

[Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].

Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS.

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Oct;29(10):679-87. Chinese.

PMID:
17129496
[PubMed - indexed for MEDLINE]
16.

Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.

Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D.

Vaccine. 2007 Jan 15;25(5):957-64. Epub 2006 Sep 11.

PMID:
17045368
[PubMed - indexed for MEDLINE]
17.

Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.

Shamji MH, Ljørring C, Francis JN, Calderon MA, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Würtzen PA, Durham SR.

Allergy. 2012 Feb;67(2):217-26. doi: 10.1111/j.1398-9995.2011.02745.x. Epub 2011 Nov 14.

PMID:
22077562
[PubMed - indexed for MEDLINE]
18.

Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.

Kleine-Tebbe J, Ribel M, Herold DA.

Allergy. 2006 Feb;61(2):181-4.

PMID:
16409193
[PubMed - indexed for MEDLINE]
19.

Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.

Panzner P, Petrás M, Sýkora T, Lesná I.

Respir Med. 2008 Sep;102(9):1296-304. doi: 10.1016/j.rmed.2008.03.024. Epub 2008 Jun 27.

PMID:
18585908
[PubMed - indexed for MEDLINE]
Free Article
20.

Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial.

Pfaar O, Klimek L.

Ann Allergy Asthma Immunol. 2008 Mar;100(3):256-63.

PMID:
18426146
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk